These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 476714)

  • 1. Phase II trial of pyrazofurin in patients with multiple myeloma refractory to standard cytotoxic therapy.
    Lake-Lewin D; Myers J; Lee BJ; Young CW
    Cancer Treat Rep; 1979 Aug; 63(8):1403-4. PubMed ID: 476714
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
    Nichols WC; Kvols LK; Ingle JN; Edmonson JH; Ahmann DL; Rubin J; O'Connell MJ
    Cancer Treat Rep; 1978 May; 62(5):837-9. PubMed ID: 657166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of pyrazofurin in malignant melanoma.
    Budman D; Currie V; Wittes R
    Cancer Treat Rep; 1977 Dec; 61(9):1733-4. PubMed ID: 340040
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
    Gockerman JP; Silberman H; Bartolucci AA
    Cancer Treat Rep; 1987; 71(7-8):773-4. PubMed ID: 3300970
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II evaluation of pyrazofurin in patients with carcinoma of the lung.
    Gralla RJ; Currie VE; Wittes RE; Golbey RB; Young CW
    Cancer Treat Rep; 1978 Mar; 62(3):451-2. PubMed ID: 348315
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II trial of pyrazofurin in advanced head and neck cancer.
    Cheng E; Currie V; Wittes RE
    Cancer Treat Rep; 1979; 63(11-12):2047-8. PubMed ID: 526937
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II evaluation of pyrazofurin in patients with advanced colorectal carcinoma.
    Carroll DS; Kemeny NE; Gralla RJ
    Cancer Treat Rep; 1979 Jan; 63(1):139-40. PubMed ID: 369686
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of pyrazofurin in advanced colorectal carcinoma.
    Creagan ET; Rubin J; Moertel CG; Schutt AJ; O'connell MJ; Hahn RG; Reitemeir RJ; Frytak S
    Cancer Treat Rep; 1977; 61(3):491-3. PubMed ID: 872147
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I study of pyrazofurin in refractory acute myelogenous leukemia.
    Vogler WR; Trulock PD
    Cancer Treat Rep; 1978 Oct; 62(10):1569-71. PubMed ID: 152146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of pyrazofurin, alone and in combination with trifluorothymidine, in non-Hodgkin's lymphoma.
    Warrell RP; Currie V; Kempin S; Young C
    Cancer Treat Rep; 1979 Aug; 63(8):1423-5. PubMed ID: 113097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of refractory acute nonlymphocytic leukemia with a combination of pyrazofurin and cytarabine.
    Kaplan HG; Appelbaum FR; Cheever MA; Greenberg PD; Wood T; Fefer A
    Cancer Treat Rep; 1982 Jun; 66(6):1397-8. PubMed ID: 7083242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial clinical study with pyrazofurin.
    Ohnuma T; Holland JF
    Cancer Treat Rep; 1977; 61(3):389-94. PubMed ID: 872139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of pyrazofurin and 5-azacytidine in refractory adult acute leukemia.
    Martelo OJ; Broun GO; Petruska PJ
    Cancer Treat Rep; 1981; 65(3-4):237-9. PubMed ID: 6165467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
    Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel R
    Cancer Treat Rep; 1986 Apr; 70(4):473-6. PubMed ID: 3698041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical trial of pyrazofurin in combination with 5-azacytidine in acute adult nonlymphocytic leukemia.
    Van Echo DA; Chiuten DF; Markus S; Wiernik PH
    Cancer Clin Trials; 1981; 4(2):129-33. PubMed ID: 6166406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: a Southwest Oncology Group Study.
    Stuckey WJ; Crowley J; Baker LH; Larrimer NR; Hanson KH; Bonnet JD; White LA
    Cancer Treat Rep; 1987 Nov; 71(11):1095-6. PubMed ID: 3119202
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II evaluation of pyrazofurin in patients with metastatic sarcoma.
    Gralla RJ; Sordillo PP; Magill GB
    Cancer Treat Rep; 1978 Oct; 62(10):1573-4. PubMed ID: 361228
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
    Gockerman JP; Bartolucci AA; Nelson MO; Silberman H; Velez-Garcia E; Stein R
    Cancer Treat Rep; 1986 Jun; 70(6):801-2. PubMed ID: 3524829
    [No Abstract]   [Full Text] [Related]  

  • 19. The therapy of myeloma. A conceptual approach.
    Jacobs P; Dubovsky D
    Cent Afr J Med; 1975 Jul; 21(7):158-60. PubMed ID: 1182791
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase I study of pyrazofurin.
    Salem PA; Bodey GP; Burgess MA; Murphy WK; Freireich EJ
    Cancer; 1977 Dec; 40(6):2806-9. PubMed ID: 589556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.